Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

2.002 Posts
Pagina: «« 1 ... 9 10 11 12 13 ... 101 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 april 2007 11:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    M.A.D.W. schreef:

    [quote=gismo74]
    Short interest van April

    www.nasdaqtrader.com/asp/short_intere...

    [/quote]

    Er staan nog veel shortaandelen uit. Kan leuk zijn als er goede datanieuws komt. Dan krijg je een grote shortsqueeze.
    Met het lage volume zal het ze nog lang duren om al die shortaandelen te coveren.
    Dat er veel short staat, betekend wel dat er veel wantrouwen is. En het is bewezen dat ze vorige keer gelijk hadden... Dus de vraag is, wie heeft er nu ongelijk ?
  2. [verwijderd] 25 april 2007 12:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Jommeke schreef:

    [quote=M.A.D.W.]
    [quote=gismo74]
    Short interest van April

    www.nasdaqtrader.com/asp/short_intere...

    [/quote]

    Er staan nog veel shortaandelen uit. Kan leuk zijn als er goede datanieuws komt. Dan krijg je een grote shortsqueeze.
    Met het lage volume zal het ze nog lang duren om al die shortaandelen te coveren.
    [/quote]
    Dat er veel short staat, betekend wel dat er veel wantrouwen is. En het is bewezen dat ze vorige keer gelijk hadden... Dus de vraag is, wie heeft er nu ongelijk ?
    Dan is het toch mooi. Laten er maar veel wantrouwen zijn. Er is ook een berichtgekomen van Insmed IR dat het management zeker geen emissie zal laten plaatsvinden op deze lage koers. Dit is voor mij ook een teken dat ze voor Q3 zeker een hogere koers verwachten of dat er misschien wel geen emissie nodig is door een vroeger geplande opt in of buyout.

    messages.finance.yahoo.com/Stocks_%28...

    Gr. Gismo
  6. [verwijderd] 25 april 2007 15:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Insmed Sees plex Phase III Trials In Early 2009
    Last update: 4/25/2007 9:08:46 AM(MORE TO FOLLOW) Dow Jones Newswires April 25, 2007 09:08 ET (13:08 GMT)
  7. [verwijderd] 25 april 2007 15:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Insmed Inc. Releases Investor Fact Sheet with Updates on Drug Development Progress
    RICHMOND, Va., Apr 25, 2007 (BUSINESS WIRE) -- Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with unmet medical needs, today released an "Investor Fact Sheet" detailing the progress of its drug development programs. The full text of the Fact Sheet is as follows:

    Focusing on Markets with Unmet Needs

    Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company engaged in the development and approval of drugs to treat patients with metabolic diseases that currently have limited or no treatment options.

    Our lead drug, IPLEX(TM), is a complex composed of recombinant human insulin-like growth factor I and insulin-like growth factor binding protein-3.

    Insmed is presently moving forward on two very specific pathways. We are continuing the development of IPLEX(TM) for additional clinical indications while concurrently studying the emerging generic biologic market, recognizing the potential opportunities that exist in this sector.

    Headquartered in Richmond, Virginia, Insmed maintains a state-of the-art FDA-approved commercial biologic manufacturing facility, Insmed Therapeutic Proteins, in Boulder, Colorado.

    Background

    In 2005 IPLEX(TM) was approved for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) and was granted orphan drug status by the United States Food and Drug Administration.

    In March 2007, Insmed settled a patent litigation suit with Tercica, Inc. and Genentech, Inc. Pursuant to the settlement, Insmed agreed to take IPLEX(TM), which had been on the market for approximately six months, off the market for Primary IGFD and discontinue development in all short stature indications. In return, we retained the right to develop IPLEX(TM) for a wide range of non-short stature indications, with larger patient populations and greater market potential.

    The IPLEX(TM) Pipeline - Targeted Research

    IPLEX(TM) is currently being studied as a treatment for several serious medical conditions, Myotonic Muscular Dystrophy (MMD); Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease; HIV-Associated Adipose Redistribution Syndrome (HARS); and retinopathy of prematurity (ROP). Cumulatively, these disorders affect more than 100,000 patients in the United States, and an equal number in the European Union, representing potential markets that could be measured in the hundreds of millions of dollars.

    Myotonic Muscular Dystrophy Research

    MMD is the most common form of adult muscular dystrophy, affecting 1 in 8,000 individuals in the United States. Approximately 40,000 Americans are diagnosed with the disease, and close to 60,000 people in the European Union also suffer from this life-threatening disorder. Patients with MMD develop progressive muscle wasting and weakness, cardiovascular problems and digestive complications. In extreme cases patients eventually become totally disabled and typically die from respiratory or cardiac failure. At present there is no treatment to halt or reverse the progression of MMD.

    IPLEX(TM) is being investigated in an ongoing open label Phase II clinical study at the University of Rochester School of Medicine, with funding provided by the Muscular Dystrophy Association and the National Institutes of Health. The objective of the Phase II study is to examine the safety, tolerability and initial efficacy of a once-daily, subcutaneous injection of IPLEX(TM) in patients with MMD.

    We expect initial data from the first of these trials to be available in the second quarter of 2007 and presented at a scientific meeting in the third quarter of 2007. We currently plan to initiate an expanded Phase II trial, with a larger number of participants, by the end of 2007 and enter Phase III clinical trials in early 2009.

    Italy Requests IPLEX(TM) for ALS Patients

    In January 2007, Insmed announced that the Italian Ministry of Health had requested IPLEX(TM) for Italian patients suffering from ALS. This life-threatening neuromuscular disease strikes adults in mid-life. In Italy approximately 1,000 new cases of ALS are diagnosed every year.

    In cooperation with Cephalon, which holds the patent for IGF-1in the European Union, Insmed is currently supplying IPLEX(TM) on a cost recovery basis to these Italian patients under an Expanded Access Program. Data collected through the Expanded Access Program in Italy will be used to design future ALS clinical development studies with IPLEX(TM).

    IPLEX(TM) for HARS

    IPLEX(TM) is being explored as a possible therapy for HARS. An estimated 80,000 HIV patients in the United States have HARS, according to published reports. This disorder is marked by abnormal metabolism including both central fat accumulation (visceral adiposity and buffalo hump) with or without fat loss in the limbs. These features have increased markedly with the advent of highly active antiretroviral therapy (HAART) for HIV. Recent studies performed in subjects on HAART suggest nearly 50% of these individuals develop the morphologic features characteristic of this syndrome.

    Preliminary data from a Phase II open-label clinical study is currently being analyzed. The study, directed by Morris Schambelan, M.D., a professor of medicine at University of California San Francisco and Chief of Endocrinology and Director of the General Clinical Research Center at San Francisco General Hospital, is designed to evaluate the safety and efficacy of 12 weeks of IPLEX(TM) treatment in subjects with HARS. The primary objective of the study is to determine the effects of IPLEX(TM) on visceral fat distribution, insulin sensitivity and glucose and lipid metabolism. We expect initial data from this trial to be available in 2007, with additional Phase II trials planned to begin in the first half of 2008 and Phase III trials planned to initiate in 2009.

    IPLEX(TM) for Retinopathy of Prematurity

    IPLEX(TM) is currently in the first phase of clinical development for the treatment of ROP. This disease, which affects an estimated 14,000 to 16,000 premature infants each year, impedes the development of the small blood vessels in the back of the eye leading to blindness in the majority of cases. A Phase I clinical study investigating IPLEX(TM) as a treatment for ROP has been initiated at the University of Gothenburg in Sweden, in collaboration with scientists at the Harvard Medical School in the United States.

    Ten patients are being enrolled sequentially, with each subsequent patient receiving a higher dose of IPLEX(TM). The objective of the study is to determine the dose of IPLEX(TM) required to increase serum IGF-1 levels into the normal physiological range. Results of this study are currently expected by the end of 2007, at which point a timeline for future clinical development will be determined.

    Beyond IPLEX(TM): Oncology Compounds

    Insmed has two oncology compounds, rhIGFBP-3 and INSM-18, in development. Both hold promising potential treatments for a variety of cancers. Preclinical models show that one or both treatments interact with the IGF-1 system to reduce tumor growth in models of breast, prostate, lung, colorectal and head and neck cancers.

    RhIGFBP-3 has demonstrated preclinical efficacy in numerous cancer indications, including breast, prostate, liver, ovarian a
  8. [verwijderd] 25 april 2007 15:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    RhIGFBP-3 has demonstrated preclinical efficacy in numerous cancer indications, including breast, prostate, liver, ovarian and colon. Additionally, several lines of recent evidence, from various cell systems, have suggested that rhIGFBP-3 may play a more active, IGF-1-independent role in growth regulation of cancer cells, binding specifically with high affinity to the surface of various cell types and directly inhibiting monolayer growth of these cells in an IGF-1-independent manner. Also recent independent studies have demonstrated that when IGFBP-3 is used in combination with other cancer therapies it can accentuate and even synergize the efficacy of standard cancer therapies. We have an ongoing open label Phase I clinical study with rhIGFBP-3 which is a dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of a single intravenous dose of rhIGFBP-3. The primary goal of this 30-patient study is to identify the appropriate dose of rhIGFBP-3 for a planned Phase II clinical trial in breast cancer patients.

    INSM-18 is an orally available, small molecule, tyrosine kinase inhibitor. It has demonstrated dual inhibition of the IGF-1 and HER2 receptors. Two single-dose Phase I clinical studies in healthy volunteers have previously been completed with this drug candidate. In both studies, the drug was safe and well-tolerated. Additionally, a Phase I-II dose escalation clinical study designed to define the maximum tolerated dose of INSM-18 in patients with relapsed prostate cancer has been completed at the University of California, San Francisco. This study consisted of a 28-day treatment period at each dose level to investigate the effect of INSM-18 on levels of prostate specific antigen (PSA). An analysis of the data collected from the study is currently being conducted, and the results will be used to design further Phase II clinical studies.

    Manufacturing Edge

    Our state-of-the-art manufacturing facility, Insmed Therapeutic Proteins (ITP), is FDA-inspected and approved. Located in the biotechnology hub of Boulder, Colorado, we believe ITP is a significant technological asset for Insmed. Given its advanced protein manufacturing capability, combined with a skilled work force, we believe we are well placed to leverage our protein development and manufacturing expertise in a number of new ventures, either through acquisitions or partnering.

    As pending legislation is paving the way for affordable and safe alternatives to existing biologics that will soon be coming off patent, we believe our ITP facility and the inherent expertise developed at the site positions Insmed for the potential development of generic biologics

    Insmed Chairman and CEO Dr. Geoffrey Allan testified at the United States House of Representatives Oversight and Government Reform Committee with respect to generic biologics on March 16, 2007, stating, "Insmed has developed significant intellectual capital focused towards protein characterization and purification. We have invested in building the facilities required to manufacture quality recombinant proteins. The combination of our proprietary protein platform with a biogeneric protein platform meets our goal to sustain innovation along with the ability to provide safe and affordable drugs to address a growing economic issue."

    Insmed has an ongoing development program in the biogeneric area. We are currently at an early stage in developing five protein products which collectively could potentially represent several billion dollars of sales in the United States market. We intend to seek a partner to undertake the commercialization of these protein products.

    Insmed Corporate Information
    Insmed Incorporated
    8720 Stony Point Parkway
    Richmond, Virginia 23235

    Dus:....................potentially represent several billion dollars of sales in the United States market. We intend to seek a partner to undertake the commercialization of these protein products.

    P. van Partner
  10. [verwijderd] 25 april 2007 15:58

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De data van MMD is Q2 beschikbaar, maar wordt deze nu pas in Q3 gepubliceerd of alleen gepresenteerd?

    "We expect initial data from the first of these trials to be available in the second quarter of 2007 and presented at a scientific meeting in the third quarter of 2007."
  11. ludwig mack 25 april 2007 16:46

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    gismo74 schreef:

    De data van MMD is Q2 beschikbaar, maar wordt deze nu pas in Q3 gepubliceerd of alleen gepresenteerd?

    "We expect initial data from the first of these trials to be available in the second quarter of 2007 and presented at a scientific meeting in the third quarter of 2007."
    dan gepresenteerd en gepublicceerd, vrijgegeven; het duurt voor twee produkten als ik het goed zie een paar maanden langer dan we dachten, maar q3 is al aan begin juli en eind q2 of begin q3 maakt niet heel veel uit. koers zal niet veel doen denk ik ..........
  13. [verwijderd] 25 april 2007 17:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    M.A.D.W. schreef:

    [quote=crackedtooth]
    Wanneer verwacht jij HARS data ?
    crackedtooth - 24 apr 07, 15:49 | Reageer | Quote | Zoek | Aanbevolen: 0

    Q2, geen meer info bekend


    ?
    :p

    [/quote]

    hahaha ikbegreep je niet goed. Dus je bedoeld dat het wel in Q2 komt. Ik zit nu vol in INSM. Ben beniuwd wat het gaat doen de komende maand.

    Verder zit ik ook ALAN te kopen op de huidige koers. Dat aandeel kan ook nog veel omhoog. Ze maken mooie winst nu. Misschien leuk aandeel voor jou Crack?
    Arme MADW, gisteren er nog vol in. Nu er weer helemaal uit. Het moet wat kosten!
  14. ludwig mack 25 april 2007 17:35

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    [Modbreak Thijs (forum@iex.nl): Dit bericht is op verzoek van de plaatser ervan verwijderd, omdat er privacygevoelige informatie in voorkwam.]
  16. [verwijderd] 25 april 2007 18:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ?? Ik snap niet wat jullie probleem is. Als we nu pas in Q3 wat te horen krijgen dan ga ik liever eerst ergens anders handelen. Ik zie de koers nu niet ver stijgen. En verlies? Ik heb rond deze koers lopen kopen. Dus ik heb hoogstens mijn aan en verkoopkosten. Maar goed over 2 maanden koop ik ze terug. Of hij moet wat lager gaan dan koop ik gelijk weer wat terug.
  17. ludwig mack 25 april 2007 18:14

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675


    na q2 krijg je insm niet meer voor deze koers: zal wellicht nog iets zakken maar dan weer wat stijgen want vallen doet ie niet;
    kost je dus provisie en een paar dollarcenten omhoog en je moet zeker weten dat je nog een andere leuke deal weet, anders is handelen nu onzin, zo denk ik er over.
    gr
  18. ludwig mack 25 april 2007 18:18

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    M.A.D.W. schreef:

    ?? Ik snap niet wat jullie probleem is. Als we nu pas in Q3 wat te horen krijgen dan ga ik liever eerst ergens anders handelen. Ik zie de koers nu niet ver stijgen. En verlies? Ik heb rond deze koers lopen kopen. Dus ik heb hoogstens mijn aan en verkoopkosten. Maar goed over 2 maanden koop ik ze terug. Of hij moet wat lager gaan dan koop ik gelijk weer wat terug.
    je leest nooit goed: bij je eerste reaktie was je positief en even later een andere conclusie; je posting krijgen dus minder waarde, van de hak op de tak, en salto's ...........en dat is het probleem.
  19. [verwijderd] 25 april 2007 18:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    quote:

    M.A.D.W. schreef:

    ?? Ik snap niet wat jullie probleem is. Als we nu pas in Q3 wat te horen krijgen dan ga ik liever eerst ergens anders handelen. Ik zie de koers nu niet ver stijgen. En verlies? Ik heb rond deze koers lopen kopen. Dus ik heb hoogstens mijn aan en verkoopkosten. Maar goed over 2 maanden koop ik ze terug. Of hij moet wat lager gaan dan koop ik gelijk weer wat terug.
    [/quote]

    [quote=ludwig mack]
    je leest nooit goed: bij je eerste reaktie was je positief en even later een andere conclusie; je posting krijgen dus minder waarde, van de hak op de tak, en salto's ...........en dat is het probleem.
    Eindelijk nog iemand die dezelfde mening is toegedaan !!!
2.002 Posts
Pagina: «« 1 ... 9 10 11 12 13 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.518
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.588
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.729
Aedifica 3 903
Aegon 3.258 322.686
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.330
Air France - KLM 1.025 35.023
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.691
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.925
AMG 971 133.200
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 490
Antonov 22.632 153.605
Aperam 92 14.975
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.659
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.293
Aroundtown SA 1 219
Arrowhead Research 5 9.729
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.089
ASML 1.766 106.424
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 14 februari

    1. Theon Q4-cijfers
    2. Hermes Q4-cijfers (Fra)
    3. Umicore Q4-cijfers
    4. Consumptie huishoudens december (NL)
    5. Economische groei vierde kwartaal vlpg (NL)
    6. Internationale handel december (NL)
    7. Economische groei vierde kwartaal 2e raming (eur) volitaliteit verwacht
    8. Moderna Q4-cijfers (VS)
    9. Detailhandelsverkopen januari (VS)
    10. Importprijzen januari (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda